Search hospitals > Illinois > Chicago
University of Chicago Comprehensive Cancer Center
Claim this profileChicago, Illinois 60637
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Tumors
Conducts research for Leukemia
Conducts research for Adenocarcinoma
594 reported clinical trials
50 medical researchers
Summary
University of Chicago Comprehensive Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Adenocarcinoma and other specialties. University of Chicago Comprehensive Cancer Center is involved with conducting 594 clinical trials across 763 conditions. There are 50 research doctors associated with this hospital, such as Rita Nanda, MD, Susan L. Cohn, Ardaman Shergill, MD, and Christine M. Bestvina.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Recurrence
Global LeaderStage IV
Stage III
Stage I
Top PIs
Rita Nanda, MDUniversity of Chicago Comprehensive Cancer Center7 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
24 reported clinical trials
47 drugs studied
Susan L. CohnUniversity of Chicago Comprehensive Cancer Center6 years of reported clinical research
Expert in Neuroblastoma
Expert in Tumors
19 reported clinical trials
38 drugs studied
Ardaman Shergill, MDUniversity of Chicago Comprehensive Cancer Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Adenocarcinoma
23 reported clinical trials
61 drugs studied
Christine M. BestvinaUniversity of Chicago Comprehensive Cancer Center5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
18 reported clinical trials
33 drugs studied
Clinical Trials running at University of Chicago Comprehensive Cancer Center
Breast Cancer
Prostate Cancer
Brain Tumor
Cancer
Lung Cancer
Acute Lymphoblastic Leukemia
Lymphoma
Tumors
Rhabdomyosarcoma
Leukemia
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Omitting Radiation Therapy
for Breast Cancer
This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Chicago Comprehensive Cancer Center?
University of Chicago Comprehensive Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Adenocarcinoma and other specialties. University of Chicago Comprehensive Cancer Center is involved with conducting 594 clinical trials across 763 conditions. There are 50 research doctors associated with this hospital, such as Rita Nanda, MD, Susan L. Cohn, Ardaman Shergill, MD, and Christine M. Bestvina.
Where is University of Chicago Comprehensive Cancer Center located?
**Directions to the Center for Care and Discovery:**
- From the north, take the Kennedy Expressway (I-90) east or Edens Expressway (I-94) south.
- Merge onto the Dan Ryan Expressway (I-90/94) east.
- Exit at 55th Street (Garfield Boulevard) and follow signs to 5700 S. Maryland Ave.
Who should I call to ask about financial aid or insurance network?
For insurance inquiries at the University of Chicago Comprehensive Cancer Center, email Benefits@uchicago.edu or call 773-702-9634. For financial assistance, download the application in English or Spanish, attach supporting documents, and mail to The University of Chicago Medicine, 150 Harvester Dr., Ste 300, Burr Ridge, IL 60527-5965. For billing questions, contact (773) 702-6664 or send mail to the same address.
What insurance does University of Chicago Comprehensive Cancer Center accept?
The University of Chicago Comprehensive Cancer Center accepts a broad spectrum of insurance plans, such as Aetna, AIG Medical, American Health Holding, Blue Cross Blue Shield PPO, Cigna, Coventry Health Care of Illinois (PersonalCare) HMO, Health Alliance PPO, Humana, Medicaid (Illinois), Medicare, MultiPlan PPO, and United Healthcare Choice Plus (POS/PPO). This includes commercial insurance plans, exchange or health insurance marketplace plans, and Medicare and Medicare Advantage insurance plans. Please contact your insurance company to confirm coverage before receiving services.
What awards or recognition has University of Chicago Comprehensive Cancer Center received?
The University of Chicago Comprehensive Cancer Center (UCCCC) has been an NCI-Designated Cancer Center since 1973 and achieved comprehensive status in 2008. It is renowned for its contributions to basic and clinical research, especially in drug development and early-phase clinical trials, enrolling about 1,000 patients annually. The center excels in genetic classification of hematological malignancies, cancer immunology, pharmacogenomics, and cancer genetics, among other areas, and has earned significant accolades including the Leapfrog Group's Top Teaching Hospital and the Magnet Recognition Program designation.